Assessment of Whole Gut Transit Time Using the SmartPill Capsule (WholeGut)
This study has been completed.
Sponsor:
The SmartPill Corporation
Information provided by:
The SmartPill Corporation
ClinicalTrials.gov Identifier:
NCT00603707
First received: January 8, 2008
Last updated: August 28, 2008
Last verified: August 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Our null hypothesis states that the two techniques (Sitzmarks radioopaque markers and SmartPill) are equivalent and is demonstrated if the study population shows a correlation of 0.7 or higher.
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Assessment of Whole Gut Transit Time Using the SmartPill Capsule: a Multi-Center Study |
Resource links provided by NLM:
Further study details as provided by The SmartPill Corporation:
Primary Outcome Measures:
- whole gut transit time [ Time Frame: 2 days and 5 days ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Determine regional gut (gastric, small bowel, colonic) transit times [ Time Frame: continuous time measure until caspule elimination ] [ Designated as safety issue: No ]
| Enrollment: | 178 |
| Study Start Date: | October 2006 |
| Study Completion Date: | June 2008 |
| Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Normal
healthy adult subjects with no history or current gastrointestinal disorders or conditions
|
|
Constipated
Adult subjects with functional constipation as define by Rome II criteria
|
Detailed Description:
The purpose of the study is to measure total gastrointestinal transit time using SmartPill GI Monitoring System with pH.p Capsule and compare the transit time determined by capsule transit to the conventional radioopaque marker technique.
Both techniques are simultaneously applied in normal and constipated adult populations.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
patients with constipation referred to a tertiary motility center
Criteria
Inclusion Criteria:
- Males and females between ages of 18-80 years of age with functional constipation that fulfills the Rome II definition of functional constipation
- Bowel movement frequency of < 3 times per week but at least once per two weeks.
- Constipation symptoms for at least 1 year duration.
- Constipation, not abdominal pain, as the primary symptom.
- Ability to stop fiber, laxatives, prokinetic agents, and narcotic analgesic agents 3 days prior to the study and during the 5 day study period.
- Ability to stop proton pump inhibitors 7 days prior to the study and H2RAs for 3 days prior to the study.
Exclusion Criteria:
- Previous history of bezoars.
- Prior GI surgery except for cholecystectomy, appendectomy, or Nissen fundoplication
- Any abdominal surgery within the past 3 months
- Known or history of inflammatory bowel disease
- History of diverticulitis, diverticular stricture, and other intestinal strictures
- Tobacco use within eight hours prior to capsule ingestion and during the initial 8 hour recording on Day 0 or the Ingestion visit.
- Alcohol use within eight hours prior to capsule ingestion and throughout the entire monitoring period (5 days).
- BMI > 38
- Allergies to components of the SmartBar (Appendix IX).
- Females of childbearing age who are not practicing birth control and/or are pregnant or lactating. (A urine pregnancy test will be performed on female subjects prior to capsule ingestion).
- Cardiovascular, endocrine, renal, or other chronic disease likely to affect motility.
- Use of medical devices such as pacemakers, infusion pumps, or insulin pumps.
- Any contraindication to use of Fleets Enema or balloon expulsion test.
- Uncontrolled diabetes with a hemoglobin A1C greater than 10.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00603707
Locations
| United States, Arizona | |
| Mayo Clinic, Scottsdale | |
| Scottsdale, Arizona, United States, 85259 | |
| United States, Iowa | |
| University of Iowa | |
| Iowa City, Iowa, United States, 52242 | |
| United States, Kansas | |
| Kansas University Medical Center | |
| Kansas City, Kansas, United States, 66160 | |
| United States, Massachusetts | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
| United States, Michigan | |
| University of Michigan Medical Center | |
| Ann Arbor, Michigan, United States, 48109 | |
| United States, New York | |
| VA Medical Center | |
| Buffalo, New York, United States, 14215 | |
| United States, North Carolina | |
| Wake Forest University Baptist Medical Center | |
| Winston-Salem, North Carolina, United States, 27157 | |
| United States, Pennsylvania | |
| Temple University Medical Center | |
| Philadelphia, Pennsylvania, United States, 19140 | |
Sponsors and Collaborators
The SmartPill Corporation
Investigators
| Study Chair: | Henry Parkman, MD | Temple University Medical Center |
More Information
No publications provided
| Responsible Party: | John R. Semler/Chief Technology Officer, The SmartPill Corporation |
| ClinicalTrials.gov Identifier: | NCT00603707 History of Changes |
| Other Study ID Numbers: | 122205 |
| Study First Received: | January 8, 2008 |
| Last Updated: | August 28, 2008 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by The SmartPill Corporation:
|
capsule constipation whole gut transit |
colonic transit gastric emptying small bowel transit |
Additional relevant MeSH terms:
|
Constipation Signs and Symptoms, Digestive Signs and Symptoms |
ClinicalTrials.gov processed this record on June 18, 2013